| Literature DB >> 27188409 |
Diego Orbegozo Cortés1, Lokmane Rahmania1, Marian Irazabal1, Carlos Santacruz1, Vito Fontana1, Daniel De Backer1, Jacques Creteur1, Jean-Louis Vincent2.
Abstract
BACKGROUND: Acute respiratory distress syndrome (ARDS) is associated with vascular endothelial dysfunction. The resultant microvascular reactivity can be assessed non-invasively using near-infrared spectroscopy (NIRS) and a vascular occlusion test (VOT) and changes have been correlated with severity of organ dysfunction and mortality in other critically ill populations. We used NIRS to study the presence of microcirculatory alterations in patients with ARDS.Entities:
Keywords: Hypoxemia; Mechanical ventilation; Microcirculation; Prognosis; Reactive hyperemia
Mesh:
Year: 2016 PMID: 27188409 PMCID: PMC4869291 DOI: 10.1186/s12931-016-0375-y
Source DB: PubMed Journal: Respir Res ISSN: 1465-9921
Fig. 1Schematic representation of tissue oxygen saturation (StO2) changes during a vascular occlusion test (VOT)
Main characteristics of the healthy volunteers and the ARDS patients at the time of the VOT
| VARIABLE | Volunteers ( | ARDS | ||
|---|---|---|---|---|
| Total ( | Good evolution ( | Poor evolution ( | ||
| Age (years) | 30 (27–31)* | 63 (48–71) | 68 (46–78) | 61 (51–66) |
| Male n(%) | 15 (56) | 21 (66) | 12 (75) | 9 (56) |
| Body mass index (Kg/m2) | 23 (22–25)* | 26 (23–29) | 25 (24–28) | 27 (22–30) |
| Mean arterial pressure (mmHg) | 88 (83–91) | 82 (75–89) | 83 (80–93) | 78 (72–87) |
| Heart rate (bpm) | 74 (70–79)* | 95 (81–104) | 96 (81–105) | 95 (83–102) |
| Respiratory rate (bpm) | 12 (12–13)* | 24 (19–30) | 23 (18–30) | 24 (20–31) |
| SpO2 | 98 (98–99)* | 97 (95–99) | 97 (95–99) | 98 (96–99) |
| Hemoglobin O2 saturation (%) | - | 97 (95–99) | 97 (95–99) | 98 (96–100) |
| Temperature (°C) | - | 37.0 (36.3-37.5) | 37.1 (36.6-37.6) | 36.7 (36.1-37.2) |
| Sepsis n(%) | - | 16 (50) | 7 (44) | 9 (56) |
| Primary ARDS n(%) | - | 9 (28) | 5 (31) | 4 (25) |
| Trauma n(%) | - | 4 (13) | 2 (13) | 2 (13) |
| Surgery n(%) | - | 18 (56) | 12 (75) | 6 (38) |
| Chronic lung disease n(%) | - | 5 (16) | 1 (6) | 4 (25) |
| Inspired O2 fraction (%) | - | 50 (40–55) | 50 (33–50) | 50 (40–70) |
| Positive end-expiratory pressure (cmH20) | - | 6 (5–8) | 7 (6–8) | 5 (5–11) |
| PaO2/FiO2 ratio | - | 172 (126–231) | 181 (126–243) | 172 (128–223) |
| pH | - | 7.39 (7.34-7.44) | 7.40 (7.34-7.44) | 7.38 (7.33-7.45) |
| PCO2 (mmHg) | - | 37 (36–44) | 37 (36–43) | 38 (35–53) |
| Lactate (mmol/L) | - | 1.4 (0.8-2.5) | 1.4 (0.8-3.2) | 1.5 (0.9-2.3) |
| Creatinine (mg/dL) | - | 1.1 (0.7-1.6) | 1.1 (0.8-1.4) | 1.0 (0.6-2.0) |
| Renal replacement therapy n(%) | - | 4 (13) | 1 (6) | 3 (19) |
| Total bilirubin (mg/dL) | - | 0.7 (0.5-1.1) | 0.6 (0.5-1.1) | 0.8 (0.6-1.3) |
| Platelets (x103/μL) | - | 129 (91–197) | 143 (84–226) | 121 (95–192) |
| Leukocytes (cells x103/μL) | - | 13.0 (9.4-16.7) | 13.9 (11.9-16.2) | 11.7 (7.6-17.9) |
| Hemoglobin (mg/dL) | - | 9.6 (8.9-11.2) | 9.6 (9.0-10.8) | 9.7 (8.6-11.5) |
| Sedation n(%) | - | 19 (59) | 8 (50) | 11 (69) |
| APACHE II score | - | 22 (19–26) | 21 (18–23) | 25 (21–28)** |
| SOFA score | - | 9 (7–13) | 8 (5–11) | 11 (7–15) |
| Norepinephrine (mcg/Kg/min) | - | 0.01 (0.00-0.17) | 0.00 (0.00-0.05) | 0.07 (0.00-0.27) |
| Dobutamine (mcg/Kg/min) | - | 0 (0–3) | 0 (0–2) | 0 (0–5) |
| ICU length of stay (days) | - | 7.7 (4.4-13.7) | 6.0 (4.0-7.7) | 11.9 (7.3-20.6)** |
| Ventilator free days at 28 days (days) | - | 21 (0–25) | 25 (24–26) | 0 (0–17)** |
| Mortality n(%) | - | 8 (25) | 0 (0) | 8 (50)** |
*significant difference at the p <0.05 level versus ARDS patients; **significant difference at the p <0.05 level versus good evolution
NIRS variables in healthy volunteers and ARDS patients
| NIRS VARIABLE | VOLUNTEERS ( | ARDS | ||||
|---|---|---|---|---|---|---|
| Total ( | Good evolution ( | Poor evolution ( | Survivors ( | Non-survivors ( | ||
| StO2 base (%) | 79 (76–81) | 75 (67–80)* | 77 (72–80) | 74 (60–80) | 77 (73–80) | 60 (59–76)* |
| THI base (au) | 14.4 (12.8-15.4) | 9.6 (6.8-10.8)** | 9.7 (7.7-10.8) | 9.0 (6.8-10.9) | 9.8 (6.8-10.8) | 7.9 (6.7-11.7) |
| StO2 max (%) | 94 (90–94) | 85 (76–90)** | 87 (82–90) | 84 (73–90) | 87 (83–93) | 73 (70–84)* |
| Desc slope (%/min) | 10.3 (8.4-11.4) | 9.6 (8.2-13.4) | 11.3 (8.7-15.8) | 8.8 (7.2-13.2) | 11.3 (8.7-15.3) | 8.1 (5.7-9.1)** |
| Asc slope (%/min) | 258 (216–306) | 185 (115–233)** | 222 (170–293) | 121 (90–209)** | 212 (165–252) | 95 (73–120)** |
* = p < 0.05 and ** = p < 0.01, ARDS patients compared to healthy volunteers, poor evolution compared to good evolution, and non-survivors compared to survivors
Fig. 2NIRS Asc slope in healthy volunteers and patients with ARDS according to evolution (a) and survival status (b). * = p < 0.05 compared with the volunteers; $ = p < 0.05 compared with patients with good evolution; # = p < 0.05 compared with the survivors
Fig. 3NIRS Asc slope in ARDS patients according to their PaO2/FiO2 ratio. * = p < 0.05 compared with the patients with a PaO2/FiO2 ratio between 201–300
Fig. 4Receiver operating characteristic (ROC) curves for Asc slope and PaO2/FiO2 ratio to predict death (right panel) or poor evolution (death or more than 7 days of mechanical ventilation; left panel)